Purine Salvage Enzymes in Lymphocytes and Granulocytes from Patients with Small-Cell Carcinoma of the Lung

  • Per Nygaard
  • Johannes Mejer
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 122B)


An impaired immune function is frequently seen in patients with malignant diseases. This suggests that the cell-mediated immune response plays a role in the defence against the development of such diseases. Disordered immune function has been associated with specific defects in some purine enzymes: adenosine deaminase (ADA), purine nucleoside phosphorylase (PNP), and 5′-nucleotidase (5′N) (1). The association between these enzyme deficiencies and the immune disorder has been explained to be due to an accumulation of purine nucleosides and nucleotides, which exert toxic effects especially on lymphoid cells. Deficiencies in other purine enzymes such as hypoxanthine phosphoribosyltransferase (HGPRT) and adenine phosphoribosyltransferase (APRT) have not been associated with immunological abnormalities.


Adenosine Deaminase Purine Nucleoside Phosphorylase Adenosine Kinase Hypoxanthine Phosphoribosyltransferase Impaired Immune Function 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. (1).
    Webster, A.D.B., North, M., Allsop, J., Asherson, G.L., and Watts, R.W.E., Clin. Exp. Immunol. 31:456 (1978).PubMedGoogle Scholar
  2. (2).
    Uberti, J., Johnson, R.M., Talley, R., and Lightbody, J.J., Cancer Res. 36:2046 (1976).PubMedGoogle Scholar
  3. (3).
    Formeister, J.F. and Tritsch, G.L., Surgery 79:111 (1976)PubMedGoogle Scholar
  4. (4).
    Mejer, J. and Nygaard, P., Leuk. Res. (1979) in press.Google Scholar
  5. (5).
    Dombernowsky, P. and Hansen, H.H., Acta Med. Scand. 204:513 (1978).PubMedCrossRefGoogle Scholar
  6. (6).
    Bøum, A., Tissue Antigens 4:269 (1974).CrossRefGoogle Scholar
  7. (7).
    Mejer, J. and Nygaard, P., in Inborn Errors of Immunity and Phagocytosis, MTP Press Ltd. England 181 (1979).CrossRefGoogle Scholar
  8. (8).
    Lowry, O.H., Rosebrough, N.J., Farr, A.L., and Randall, R.J., J. Biol. Chem. 193:256 (1951).Google Scholar
  9. (9).
    Borgers, M., Verhaegen, H., De Brabander, M., Thone, F., Van Reempts, J., and Geuens, G., J. Immunol. 16:101 (1977).Google Scholar
  10. (10).
    Gross, R.L., Latty, A., Williams, E.A., and Newberne, P.M., New Engl. J. Med. 292:439 (1975)CrossRefGoogle Scholar
  11. (11).
    Tung, R., Silber, R., Quagliata, F., Conklyn, M., Gottesman, J., and Hirschhorn, R., J. Clin. Invest. 57–756 (1976).Google Scholar
  12. (12).
    Sidi, Y., Boer, P., Pick, I., Pinkhas, J., and Sperling, O., Lancet. 500 (1979).Google Scholar
  13. (13).
    Ambrogi, F., Grassi, B., Ronca-Testoni, S., and Ronca, G., Clin. Exp. Immunol. 28:80 (1977).PubMedGoogle Scholar
  14. (14).
    Hadden, J.W., in The Pharmacology of Immunoregulation (ed. G.H. Werner & F. Floch) Acad. Press New York 369 (1978).Google Scholar
  15. (15).
    Asano, T. and Spector, S., Proc. Natl. Acad. Sci. (USA) 76:977 (1979).CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1980

Authors and Affiliations

  • Per Nygaard
    • 1
    • 2
  • Johannes Mejer
    • 1
    • 2
  1. 1.University Institute of Biological Chemistry BCopenhagenDenmark
  2. 2.Department of Medicine C and BloodbankBispebjerg HospitalCopenhagenDenmark

Personalised recommendations